Breakthrough Study Identifies Antibodies with Potential to Treat and Prevent West Nile Virus
A collaborative study has identified monoclonal antibodies from recovered West Nile virus patients in Serbia that show promise for both prevention and treatment of the disease.
Key Findings from the Study
- A collaborative study published in Immunity analyzed blood samples from West Nile virus (WNV) convalescents in Serbia.
- Researchers identified monoclonal antibodies with potential for prophylaxis and therapy against WNV and related orthoflaviviruses.
- Antibody W010 binds to a site on the virus envelope domain III and protected mice when administered before or up to 5 days after WNV exposure.
- Antibody W014 showed broader cross-neutralization against Japanese encephalitis, Murray Valley encephalitis, Saint Louis encephalitis, and Usutu viruses.
- The findings define vulnerable sites on WNV that could inform vaccine development.
The Urgent Need for Countermeasures
WNV is transmitted by mosquitoes and can cause severe brain infection and death. Currently, no specific antiviral treatment or approved human vaccine exists for the disease.
These results highlight promising avenues for developing human therapies and vaccines against a virus that poses a growing public health threat.